74 related articles for article (PubMed ID: 15735020)
1. Cytoplasmic domain of proEGF affects distribution and post-translational modification of microtubuli and increases microtubule-associated proteins 1b and 2 production in human thyroid carcinoma cells.
Pyka J; Glogowska A; Dralle H; Hoang-Vu C; Klonisch T
Cancer Res; 2005 Feb; 65(4):1343-51. PubMed ID: 15735020
[TBL] [Abstract][Full Text] [Related]
2. The cytoplasmic domain of proEGF negatively regulates motility and elastinolytic activity in thyroid carcinoma cells.
Glogowska A; Pyka J; Kehlen A; Los M; Perumal P; Weber E; Cheng SY; Hoang-Vu C; Klonisch T
Neoplasia; 2008 Oct; 10(10):1120-30. PubMed ID: 18813355
[TBL] [Abstract][Full Text] [Related]
3. INSL-3 is expressed in human hyperplastic and neoplastic thyrocytes.
Hombach-Klonisch S; Hoang-Vu C; Kehlen A; Hinze R; Holzhausen HJ; Weber E; Fischer B; Dralle H; Klonisch T
Int J Oncol; 2003 May; 22(5):993-1001. PubMed ID: 12684664
[TBL] [Abstract][Full Text] [Related]
4. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
[TBL] [Abstract][Full Text] [Related]
5. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
6. The C-terminal cytoplasmic domain of human proEGF is a negative modulator of body and organ weights in transgenic mice.
Klonisch T; Glogowska A; Gratao AA; Grzech M; Nistor A; Torchia M; Weber E; de Angelis MH; Rathkolb B; Cuong HV; Wolf E; Schneider MR
FEBS Lett; 2009 Apr; 583(8):1349-57. PubMed ID: 19328792
[TBL] [Abstract][Full Text] [Related]
7. The cellular localization of autotaxin impacts on its biological functions in human thyroid carcinoma cells.
Seifert A; Klonisch T; Wulfaenger J; Haag F; Dralle H; Langner J; Hoang-Vu C; Kehlen A
Oncol Rep; 2008 Jun; 19(6):1485-91. PubMed ID: 18497954
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ.
Magro G; Schiappacassi M; Perissinotto D; Corsaro A; Borghese C; Belfiore A; Colombatti A; Grasso S; Botti C; Bombardieri E; Perris R
J Pathol; 2003 Jul; 200(3):357-69. PubMed ID: 12845632
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of valosin-containing protein (p97) is correlated with disease recurrence in follicular thyroid cancer.
Yamamoto S; Tomita Y; Uruno T; Hoshida Y; Qiu Y; Iizuka N; Nakamichi I; Miyauchi A; Aozasa K
Ann Surg Oncol; 2005 Nov; 12(11):925-34. PubMed ID: 16189643
[TBL] [Abstract][Full Text] [Related]
11. Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma.
Ito Y; Yoshida H; Uruno T; Nakano K; Miya A; Kobayashi K; Yokozawa T; Matsuzuka F; Matsuura N; Kakudo K; Kuma K; Miyauchi A
Oncol Rep; 2003; 10(5):1337-40. PubMed ID: 12883703
[TBL] [Abstract][Full Text] [Related]
12. Novel isoforms of tau that lack the microtubule-binding domain.
Luo MH; Tse SW; Memmott J; Andreadis A
J Neurochem; 2004 Jul; 90(2):340-51. PubMed ID: 15228591
[TBL] [Abstract][Full Text] [Related]
13. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer.
Cheng S; Liu W; Mercado M; Ezzat S; Asa SL
Endocr Relat Cancer; 2009 Jun; 16(2):455-66. PubMed ID: 19261683
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma.
Lam AK; Lo CY; Leung P; Lang BH; Chan WF; Luk JM
Ann Surg Oncol; 2007 May; 14(5):1772-9. PubMed ID: 17195959
[TBL] [Abstract][Full Text] [Related]
15. Microtubule-associated protein 1B interaction with tubulin tyrosine ligase contributes to the control of microtubule tyrosination.
Utreras E; Jiménez-Mateos EM; Contreras-Vallejos E; Tortosa E; Pérez M; Rojas S; Saragoni L; Maccioni RB; Avila J; González-Billault C
Dev Neurosci; 2008; 30(1-3):200-10. PubMed ID: 18075266
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.
Lang BH; Lo CY; Chan WF; Lam KY; Wan KY
Ann Surg Oncol; 2007 Feb; 14(2):730-8. PubMed ID: 17103065
[TBL] [Abstract][Full Text] [Related]
18. Nuclear localisation of endogenous SUMO-1-modified PDGF-C in human thyroid tissue and cell lines.
Reigstad LJ; Martinez A; Varhaug JE; Lillehaug JR
Exp Cell Res; 2006 Apr; 312(6):782-95. PubMed ID: 16443219
[TBL] [Abstract][Full Text] [Related]
19. Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.
Ulivieri A; Lavra L; Dominici R; Giacomelli L; Brunetti E; Sciacca L; Trovato M; Barresi G; Foukakis T; Jia-Jing L; Larsson C; Bartolazzi A; Sciacchitano S
J Pathol; 2008 May; 215(1):87-96. PubMed ID: 18306168
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
